发明名称 |
Combination of lenalidomide or pomalidomide and CD38 antibody-attenuated interferon-alpha constructs, and the use thereof |
摘要 |
Methods for cancer treatment include administering to a cancer patient an anti- CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia. |
申请公布号 |
AU2015265624(A1) |
申请公布日期 |
2016.11.10 |
申请号 |
AU20150265624 |
申请日期 |
2015.05.01 |
申请人 |
Teva Pharmaceuticals Australia Pty Ltd |
发明人 |
Pogue, Sarah L.;Wilson, David S.;Doyle, Anthony Gerard;Behrens, Collette Jane |
分类号 |
C07K16/46;A61K31/454;A61K38/21;A61K39/395;A61P35/00;C07K14/56;C07K16/30 |
主分类号 |
C07K16/46 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|